Industry News

Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site

* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealand * In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via...

2021-06-02 06:00 2193

Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting

BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held fromJune 4th to 8th. The first trial (poster #2580; NCT04481009) is designed to assess the safety...

2021-06-02 01:28 2012

New Digital Intelligence Drive, New Finance

HANGZHOU, China, June 1, 2021 /PRNewswire/ -- Sunyard Technology, a leading global payment solution provider, together with the industry's well-known media "Electronic FinanceMagazine", jointly held the 2021 Yangtze River Delta Digital Finance Forum in Sheraton Hangzhou onMay 20, achieving a reso...

2021-06-02 01:00 3246